ClinicalTrials.gg
CompletedNCT02711228Updated Feb 26, 2018

Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

A Phase 4 interventional study of Subcutaneous Immune Globulin (Human) (Hizentra) in Primary Immune Deficiency and Secondary Immune Deficiency, sponsored by CSL Behring. Completed at 2 sites in Canada. Open to participants aged 5 Years to 64 Years. Per ClinicalTrials.gov, last updated 2018-02-26.

Sponsored by CSL Behring (part of CSL Limited) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
5 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.

Enrollment
6th of 13
26 · median 25
Started
2016
the only one that year
Phase 4
4 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2016, is one of 4 in phase 4, and was the 12th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 5 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Primary Immunodeficiency Diseases by CSL Limited as a file.
02

Study summary

The purpose of the study is to assess the impact of immunoglobulin treatment by subcutaneous injections every 2 weeks (biweekly) on a cohort of patients with primary and secondary immune deficiencies. The full study will consist of safety, efficacy and Quality of Life (QoL) evaluations and a pharmacokinetic (PK) sub-study. The primary objectives of the study are to determine tolerability and safety of biweekly IgPro20 injection regimen and to compare PK outcomes on weekly and biweekly IgPro20 therapy.

Patients who have received and/or are currently receiving immunoglobulin G (IgG) in intravenous (IVIg), or subcutaneous (SCIg) infusions are eligible for inclusion if they meet inclusion/exclusion criteria.

The study consists of two parts. In Part 1 of the study enrolled subjects will receive IgPro20 weekly for either 12 weeks (for patients on SCIg infusion prior to the study) or 24 weeks (for patients on IVIg infusion prior to the study). Part 2 will consist of a biweekly treatment with IgPro20 for 52 weeks, for both groups.

Additionally, study subjects meeting inclusion criteria for the PK sub-study will undergo a PK sample collection for 1 week and 2 weeks in study Parts 1 and 2, respectively.

03

Conditions studied

  • Primary Immune Deficiency
  • Secondary Immune Deficiency
04

Who can participate

Ages eligible
5 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Full study:

  • Female or male patients with primary or secondary immunodeficiency, aged from 5 to 64 years, receiving steady state immunoglobulin G replacement therapy.

Pharmacokinetic sub-study:

  • Female or male patients with primary immunodeficiency, aged between 12 and 64 years of age, on steady-state IgPro20 replacement therapy and willing to undergo pharmacokinetic sample collection on weekly and biweekly IgPro20 dosing regimens.

Exclusion criteria

Exclusion Criteria:

  • Patients with protein losing conditions such as: lymphangiectasis, nephrosis, status post cardio-thoracic surgery requiring drainage tubes for more than 48 hours, protein-losing enteropathy.
  • Concomitant treatment with plasma or other blood products (including any IgGs other than IgPro20 [Hizentra]) within 21 days before study entry and/or during the study.
  • Any other condition or treatment that, in the opinion of the investigator, would interfere with obtaining valid results for that subject.
  • Women of with a positive pregnancy test.
  • Active infection at the time of screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Subcutaneous Immune Globulin (Human) (Hizentra)

    Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.

    Biological: Subcutaneous Immune Globulin (Human) (Hizentra)

Interventions

  • Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.

    Also known as: IgPro20, Hizentra

06

What researchers measure

Primary outcomes

  1. Annualized rate of adverse events (local and systemic)

    Time frame: During biweekly treatment period, up to approximately 52 weeks

  2. Area under the concentration-time curve, AUC(0-t )

    Time frame: Immediately before, and up to 7 days after infusion during the weekly treatment period and up to 14 days after infusion during the biweekly treatment periods.

  3. Maximal serum IgG concentration (Cmax)

    Time frame: Up to 7 days after infusion during the weekly treatment period and up to 14 days after infusion during the biweekly treatment periods.

  4. Time to maximal serum IgG concentration (Tmax)

    Time frame: Up to 7 days after infusion during the weekly treatment period and up to 14 days after infusion during the biweekly treatment periods.

  5. Trough serum IgG concentration (Ctrough)

    Time frame: Immediately before, and up to 7 days after infusion during the weekly treatment period and up to 14 days after infusion during the biweekly treatment periods.

Secondary outcomes

  1. Annualized rate of infections per patient

    Time frame: During weekly and biweekly treatment periods, up to approximately 64 - 76 weeks

  2. Serum IgG trough levels (Ctrough)

    Time frame: On day 7 (immediately before each next infusion) during the weekly treatment period, and on week 24 and 48 of biweekly treatment.

  3. Health-related Quality of Life

    Time frame: During weekly and biweekly treatment periods, up to approximately 64 - 76 weeks

07

Study locations

2 sites
  • Centre Hospitalier de l'université de Montréal
    Montreal, QC H2W 1T7, Canada
  • CHU Sainte-Justine
    Montreal, QC H3T 1C4, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Jan 2018, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2016
First posted
Mar 17, 2016
StartActual
Mar 15, 2016
Primary completionActual
Jan 30, 2018
CompletionActual
Jan 30, 2018
Last update
Feb 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02711228
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Mar 17, 2016
Start date
Mar 15, 2016
Primary completion
Jan 30, 2018
Completion
Jan 30, 2018
Last update
Feb 26, 2018

Study contacts

Elie Haddad, MD
principal investigator · St. Justine's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins

Start the discussion